Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Champions Oncology, Inc.NASDAQ: CSBR

Net Income · Q3 FY2026 · quarter ended Jan 2026

Net income turns negative

Q3 FY2026 net income was -$278K, compared with $4.5M a year earlier. Trailing-twelve-month net income was -$2.34M. Over 3 fiscal years it compounded at +104.7% a year.

Context

  • Net income amounted to 8.3% of revenue in FY2025, down 6.3 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of $1.66M (-64.7%) for the fiscal year ending Apr 2026, a slowdown from the +164.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJan 2026
-$278K-217.8% QoQ
Last fiscal yearApr 2025
$4.7M+164.6% YoY
LTMJan 2026
-$2.34M-136.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-106.2%-62.1%+44.1 pp
1 year+164.6%-64.7%-229.3 pp
3-year CAGR+104.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
4.7M USD
Year-over-year change
+164.6%
4-year CAGR
+93.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -136.5% is the lowest of 9, against a peer median of +0.1%.
  • Net income amounts to 4.0% of revenue for CSBR, versus a peer median of 4987.4%.
CSBR Competitors
Net Income for CSBR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$153.6M USD-37.4%+17.0%154.2%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$110M USD+489.6%——
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$87.07M USD+21.4%+12.6%—
CNTBConnect Biopharma Holdings LimitedFY2025$55.48M USD+255.0%-21.8%86687.5%
STTKShattuck Labs, Inc.LTM Mar 2026$49.87M USD-29.4%-21.8%4987.4%
IMAImageneBio IncLTM Mar 2026$45.07M USD+8.1%-8.7%—
KLRSKalaris Therapeutics IncLTM Mar 2026$44.1M USD—+41.0%—
IFRXInflaRx N.V.LTM Mar 2026€41.2M EUR-7.9%+14.1%140477.1%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$9.47M USD-39.5%—40.9%
CSBRChampions Oncology, Inc.LTM Jan 2026$2.34M USD-136.5%+104.7%4.0%
Peer median (excluding CSBR) —+0.1%+12.6%4987.4%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Net Income334K548K(5.34M)(7.28M)4.7M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
Deferred Income Tax49K01M00
Stock-Based Compensation598K912K864K1.12M654K
Change in Working Capital(4.17M)2.34M4.23M(3.82M)(621K)
Accounts Receivables(2.27M)(2.82M)1.31M(1.99M)(1.44M)
Inventory(1.1M)0000
Accounts Payables(1.25M)974K2.47M465K(1.75M)
Other Working Capital441K4.18M470K(2.3M)2.56M
Other Non-Cash Items323K1.07M952K1.98M1.01M
Operating Cash Flow(1.68M)6.5M3.96M(6.14M)7.39M
Capital Expenditures(3.28M)(2.38M)(2.87M)(836K)(389K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities112K0000
Investing Cash Flow(3.17M)(2.38M)(2.87M)(836K)(389K)
Debt Repayment(174K)00(146K)(150K)
Common Stock Issued1.37M207K85K253K320K
Common Stock Repurchased00(74K)(634K)0
Dividends Paid00000
Other Financing Activities0085K253K0
Financing Cash Flow1.2M207K11K(527K)170K
Effect of Forex Changes0017K00
Net Change in Cash(3.66M)4.32M1.11M(7.5M)7.17M
Free Cash Flow(4.96M)4.11M1.08M(6.97M)7M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.